Healthcare Logic for Growth

In Q1 2026, nearly 60% of digital health investment went to just 12 mega-deals of $100 million or more. This episode breaks down what this funding concentration means for startups and smaller healthcare companies, and provides a practical go-forward strategy for navigating the new reality.

Key Topics Covered:

Resources & Data Sources:

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

In this episode of Healthcare Logic for Growth, we talked about why digital health companies must prove clinical value, not just engagement. We covered why activity metrics like downloads and retention are no longer enough on their own, why investors and health systems want stronger evidence, and why startups often struggle to generate proof within limited runway.

We also walked through a practical go-forward strategy for defining the outcome you need to prove, matching evidence to the buyer, limiting metrics, and connecting proof to adoption. Finally, we briefly discussed how Life Science Logic helps companies think through the path from product to proof to commercialization through GTM Sprint, GTM Crossroads, CIB, Advisory Services, and Commercialization Services.

Resources:

We looked at a PubMed article, “Applying Evidence-Based Medicine Standards to Digital Tools,” which argues that digital health tools should meet evidence expectations similar to other clinical interventions. pubmed.ncbi.nlm.nih

We also reviewed the Lancet Digital Health article, “Advancing digital health applications: priorities for innovation in real-world evidence generation,” which discusses the importance of real-world evidence in digital medicine. thelancet

Another important source was the npj Digital Medicine article, “Digital therapeutics from bench to bedside,” which covers the role of real-world evidence, commercialization, and barriers to broader adoption. nature

We also referenced a digital health commercialization framework from MIT, which helps support the broader strategy discussion.dspace.mit+1

And we looked at a recent Healthcare Logic for Growth episode that focused on what healthcare startups need to do to win, including proving outcomes, fitting workflow, and building the payment model early. Published on Spotify, Apple Podcasts, iHeart Rdio and YT

And lastly, we used the Life Science Logic Intelligence Engine, our internal life sciences AI, to help synthesize the evidence and sharpen the strategic takeaways for this episode.

Have a question or topic you'd like us to cover? Reach out to us at [email protected]

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation. 

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

Why growing in home health care requires a new staffing, reimbursement, and service design model—and what small agencies need to check before accepting new referrals.

Key Topics:

Go Forward Strategy - 5 Actions:

Resource Mentioned:

Building A Potential Tool for Home-Based Care Margin Mapping (based on 10-15 followers or subscriptions)

Follow & Subscribe:

Don't miss an episode! Subscribe to Healthcare Logic for Growth on wherever you get your podcasts.

Apple Podcasts:

https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182

Spotify:

https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3

YouTube:

https://www.youtube.com/@HealthcareLogicforGrowth

Have a question or topic you'd like us to cover? Reach out to us at [email protected]

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

In this episode of Healthcare Logic for Growth, we break down the pivotal trends from the first half of 2026 that every small and start-up healthcare company needs to know. We explore the good news (rebounding venture funding, FDA fast-track vouchers, and digital health pilot programs), the bad news (FDA staffing shortages, drug pricing uncertainty, and OMB grant threats), and the "data trap" catch-22 that is stifling early-stage biotechs. We share 10 actionable steps to help you navigate the next six months with confidence.

Sources Referenced in This Episode:

- HSBC Innovation Banking – US Healthcare Venture Investment Report: Provided the $60 billion funding data and the trend of investors demanding later-stage traction from seed-stage companies.

- PharmaVoice – Life Sciences 2026 Outlook & FDA Staffing Analysis: Sourced the quotes on FDA staffing challenges post-DOGE and the uncertainty surrounding political appointees at the agency.

- FDA Official Guidance & Pilot Programs (2026):

- Commissioner’s National Priority Voucher Program (Fast-track review).

- TEMPO Pilot Program (Enforcement discretion for digital health technologies).

- Revised Guidance on Low-Risk Wellness & Clinical Decision Support Software.

- CMS – ACCESS Model Demonstration: Source for the outcomes-based reimbursement model for digital health and medical devices.

- Federal Register / OMB – Proposed Rule on Grant Cancellations (May 2026): Source for the non-scientific criteria clause affecting SBIR and NIH grants.

- White House Executive Orders – Most Favored Nation Pricing & IRA Implementation Updates: Source for drug pricing pressures.

- Congressional Bills – Biotech Workforce Development & Biosecure Act: Source for talent pipeline initiatives and supply chain manufacturing restrictions.

- Industry Venture Capital Panel Discussions (Q1/Q2 2026) – various: Sourced the "ship at 92%" mentality and the commercial leadership cautionary tale.

Follow & Subscribe:

Don't miss an episode! Subscribe to Healthcare Logic for Growth on wherever you get your podcasts.

Apple Podcasts:

https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182

Spotify:

https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3

YouTube:

https://www.youtube.com/@HealthcareLogicforGrowth

Have a question or topic you'd like us to cover? Reach out to us at [email protected]

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns.

We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company.

Sources Referenced in This Episode:

- AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination.

- Omada public platform information on outcomes and care delivery.

- AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings.

- Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements.

- STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity.

- Public materials on Theranos’s failures and regulatory issues.

- Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges.

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans.

BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.

Sources Referenced in This Episode:

Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026

BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026

Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026

AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026

BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026"

PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026

BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org

White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:

Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider.

Sources Referenced:

About Life Science Logic:

Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier.

Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.

Sources Referenced in This Episode:

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

Healthcare is deploying AI tools at more than twice the rate of the broader economy — and for the first time at meaningful scale, the ROI is real and documented. In this episode, we unpack the NVIDIA State of AI in Healthcare 2026 survey and this week's Healthcare IT News report on AI payment alignment to answer the question every small healthcare company is quietly asking: what does the AI inflection point actually mean for my business right now? We cover three real-world scenarios across six audience segments — hospitals, home health agencies, digital health startups, pharma, biotech, and healthcare associations — and close with six specific actions you can take this week.

Links:

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

On May 1st, 2026, Nebraska became the first state in the country to enforce Medicaid work requirements under the One Big Beautiful Bill Act - the sweeping federal law that includes nearly a trillion dollars in Medicaid cuts over ten years. Montana goes live July 1st. Iowa in December. And 43 states are federally required to follow by January 1st, 2027. In this episode, we break down what this means for small life science and healthcare companies, why the 2027 framing is the wrong planning frame, and five specific steps you should be taking right now to protect your revenue model and your commercial strategy.

Sources Referenced in This Episode:

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at [email protected].

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic